Eye drops for mild to moderate limbal stem cell deficiency
Part of Eyes & vision clinical trials.
This trial tests an eye drop called BRM421 for people with mild to moderate limbal stem cell deficiency, a condition where the eye's surface doesn't heal properly. The goal is to see if this eye drop helps improve the eye's surface and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 or older).
- You have mild to moderate limbal stem cell deficiency (a condition where the eye's surface doesn't heal properly).
- You have tried standard treatments but are not satisfied with the results.
- If you are of childbearing age, you must use birth control and have a negative pregnancy test.
- You cannot have a genetic cause for your limbal stem cell deficiency.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new eye drop called CSB-001 for people with limbal stem cell deficiency (LSCD), a condition that damages the cornea. The goal is to see if the drops can help improve the health of the cornea and reduce inflammation.
This trial tests an eye treatment made from your own cornea surface cells, grown in a lab and put back into the eye. It may help people with limbal stem cell deficiency by improving the health of the eye surface after a cell biopsy.
This trial tests a treatment that uses your own eye cells to repair the surface of the eye. It may help if you have severe damage to the clear front layer of your eye.
This observational study follows patients with limbal stem cell deficiency (a condition affecting cells at the edge of the cornea that help maintain healthy eye surface) to understand how their vision changes over time. Researchers will track your eye health without giving you new treatment.
This study tests a new eye drop (BRM421) for people with dry eye disease. It aims to see if different doses can help relieve dry eye symptoms.
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
Hear when a new Limbal Stem Cell Deficiency (LSCD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.